UBS Reiterates Neutral On Exxon Mobil Following Investor Meetings
In a research report published this morning, UBS analyst William Featherston reiterated a Neutral rating on Exxon Mobil (NYSE:XOM) with a $95 price …
Credit Suisse Reiterates Underperform On Blackberry Ahead Of 3Q15 Results
In a research report released today, Credit Suisse analyst Kulbinder Garcha reiterated an Underperform rating on Blackberry (NASDAQ:BBRY) with a $6 price target, ahead …
Evercore Maintains Hold On Spirit Airlines Shares, $85 PT
In a research report published today, Evercore ISI analyst Duane Pfennigwerth maintained a Hold rating on Spirit Airlines (NASDAQ:SAVE) with an $85 price …
Prospect Capital: We Do Not Believe Current Levels Are An Attractive Entry Point, Says Wells Fargo
In a research report released today, Wells Fargo analyst Jonathan Bock reaffirmed a Market Perform rating on Prospect Capital (NASDAQ:PSEC), following the company’s announcement …
H.C. Wainwright Reaffirms Buy On Synthetic Biologics, Sees 186% Upside
In a research report published today, H.C.
RXi Pharmaceuticals Represents An Undervalued Player With Significant Upside, Says H.C. Wainwright
In a research note issued today, H.C.
Cantor Fitzgerald Reaffirms Buy On Threshold Pharmaceuticals Following Strong GBM Data
In a research note released today, Cantor Fitzgerald analyst Daniel Brims reaffirmed a Buy rating on Threshold Pharmaceuticals (NASDAQ:THLD) with a $14 price …
Cantor Fitzgerald Maintains Hold On Sunesis Pharma, Sees 6% Downside For The Stock
In a research note published this morning, Cantor Fitzgerald analyst Mara Goldstein maintained a Hold rating on Sunesis Pharmaceuticals (NASDAQ:SNSS) with a $2 …
H.C. Wainwright Reiterates Buy On Capricor Following 3Q14 Results
In a research note issued today, H.C.
GenVec Represents An Undervalued Innovator In The Gene Therapy Arena, Says H.C. Wainwright
In a research note published today, H.C.